{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:56:22Z","timestamp":1778262982787,"version":"3.51.4"},"reference-count":77,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.jocn.2012.12.022","type":"journal-article","created":{"date-parts":[[2013,8,2]],"date-time":"2013-08-02T17:01:31Z","timestamp":1375462891000},"page":"12-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Neuromyelitis optica: Concept, immunology and treatment"],"prefix":"10.1016","volume":"21","author":[{"given":"Akiyuki","family":"Uzawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2012.12.022_b0005","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2012.12.022_b0010","first-page":"1033","article-title":"My \u00e9lite subaigu\u00eb compliqu\u00e9e de n\u00e9vrite optique","volume":"8","author":"Devic","year":"1894","journal-title":"Bull Med (Paris)"},{"key":"10.1016\/j.jocn.2012.12.022_b0015","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2012.12.022_b0020","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.jocn.2012.12.022_b0025","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jns.2011.02.018","article-title":"Neuromyelitis optica and astrocytic damage in its pathogenesis","volume":"306","author":"Fujihara","year":"2011","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2012.12.022_b0030","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1007\/s00415-011-6384-3","article-title":"When is neuromyelitis optica diagnosed after disease onset?","volume":"259","author":"Uzawa","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2012.12.022_b0035","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1212\/WNL.0b013e3182190f74","article-title":"A population-based study of neuromyelitis optica in Caucasians","volume":"76","author":"Asgari","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2012.12.022_b0040","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1212\/WNL.0b013e3181d31e35","article-title":"Neuromyelitis optica in France: a multicenter study of 125 patients","volume":"74","author":"Collongues","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2012.12.022_b0045","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/jnnp.2007.143529","article-title":"Relapsing neuromyelitis optica: long term history and clinical predictors of death","volume":"80","author":"Cabre","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2012.12.022_b0050","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/jnnp-2011-300403","article-title":"Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes","volume":"82","author":"Nagaishi","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2012.12.022_b0055","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1007\/s00415-009-5274-4","article-title":"Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis","volume":"256","author":"Uzawa","year":"2009","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2012.12.022_b0060","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1177\/1352458510379247","article-title":"Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6","volume":"16","author":"Uzawa","year":"2010","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2012.12.022_b0065","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1471-2377-10-113","article-title":"Expression of chemokine receptors on peripheral blood lymphocytes in multiple sclerosis and neuromyelitis optica","volume":"10","author":"Uzawa","year":"2010","journal-title":"BMC Neurol"},{"key":"10.1016\/j.jocn.2012.12.022_b0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0b013e3181c919ee","article-title":"B-cell activating factor of the TNF family is upregulated in neuromyelitis optica","volume":"74","author":"Okada","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2012.12.022_b0075","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/brain\/awm047","article-title":"Loss of aquaporin-4 in lesions of neuromyelitis optica: distinction from multiple sclerosis","volume":"130","author":"Misu","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.jocn.2012.12.022_b0080","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/brain\/awl371","article-title":"Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis","volume":"130","author":"Roemer","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.jocn.2012.12.022_b0085","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1468-1331.2009.02897.x","article-title":"Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis","volume":"17","author":"Uzawa","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jocn.2012.12.022_b0090","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1177\/1352458507077189","article-title":"Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis","volume":"13","author":"Watanabe","year":"2007","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2012.12.022_b0095","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictor of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2012.12.022_b0100","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jocn.2012.12.022_b0105","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archneurol.2010.322","article-title":"Efficacy and safety of mithoxantrone in patients with highly relapsing neuromyelitis optica","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jocn.2012.12.022_b0110","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating B cells in patients with relapsing neuromyeltis optica","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jocn.2012.12.022_b0115","first-page":"827","article-title":"A case of acute myelitis and blindness","volume":"5","author":"Aoyama","year":"1891","journal-title":"J Tokyo Med Assoc"},{"key":"10.1016\/j.jocn.2012.12.022_b0120","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0140-6736(02)68218-2","article-title":"On the ophthalmoscopic signs of spinal disease","volume":"95","author":"Albutt","year":"1870","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2012.12.022_b0125","unstructured":"Gault F. De la neuromy\u00e9lite optique aigu\u00eb. Lyon 1894 (thesis)."},{"key":"10.1016\/j.jocn.2012.12.022_b0130","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archneurol.2012.314","article-title":"Epidemiology of neuromyelitis optica in the United States: a multicenter analysis epidemiology of NMO","volume":"69","author":"Mealy","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jocn.2012.12.022_b0135","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00415-009-0009-0","article-title":"An epidemiological study of neuromyelitis optica in Cuba","volume":"256","author":"Cabrera-G\u00f3mez","year":"2009","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2012.12.022_b0140","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s00415-008-0781-2","article-title":"Characteristics of Devic\u2019s disease (neuromyelitis optica) in Mexico","volume":"255","author":"Rivera","year":"2008","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2012.12.022_b0145","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1468-1331.2011.03529.x","article-title":"The prevalence of neuromyelitis optica in South East Wales","volume":"19","author":"Cossburn","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jocn.2012.12.022_b0150","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.clineuro.2012.01.022","article-title":"Anti-aquaporin-4 antibody in Chinese patients with central nervous system inflammatory demyelinating disorders","volume":"114","author":"Long","year":"2012","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.jocn.2012.12.022_b0155","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1212\/WNL.0b013e31822c61b1","article-title":"AQP4 antibody-positive Thai cases: clinical features and diagnostic problems","volume":"77","author":"Siritho","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2012.12.022_b0160","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1177\/1352458510376640","article-title":"Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity","volume":"16","author":"Kim","year":"2010","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2012.12.022_b0390","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/1352458512452332","article-title":"Seasonality of multiple sclerosis and neuromyelitis optica exacerbations in Japan","volume":"19","author":"Muto","year":"2013","journal-title":"Mult Scler."},{"key":"10.1016\/j.jocn.2012.12.022_b0170","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1212\/WNL.38.2.180","article-title":"MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT","volume":"38","author":"Paty","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2012.12.022_b0175","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1212\/WNL.0b013e3181e2414b","article-title":"Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study","volume":"75","author":"Takano","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2012.12.022_b0180","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","article-title":"Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre","volume":"130","author":"Takahashi","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.jocn.2012.12.022_b0185","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1371\/journal.pmed.0040133","article-title":"Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica","volume":"4","author":"Paul","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.jocn.2012.12.022_b0190","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jneuroim.2008.03.009","article-title":"Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay","volume":"196","author":"Hayakawa","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jocn.2012.12.022_b0195","first-page":"99","article-title":"Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays","volume":"15","author":"Waters","year":"2008","journal-title":"Int MS J"},{"key":"10.1016\/j.jocn.2012.12.022_b0200","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","article-title":"Serologic diagnosis of NMO: a multicente comparison of aquaporin-4-IgG assays","volume":"78","author":"Waters","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2012.12.022_b0205","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1212\/01.WNL.0000049912.02954.2C","article-title":"Neuromyelitis optica: clinical predictors of a relapsing course and survival","volume":"60","author":"Wingerchuk","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2012.12.022_b0210","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.jocn.2012.12.022_b0215","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/jnnp.2011.241760","article-title":"CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse","volume":"83","author":"Uzawa","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2012.12.022_b0220","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1212\/WNL.0b013e318250d812","article-title":"Influence of pregnancy on neuromyelitis optica spectrum disorder","volume":"78","author":"Kim","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2012.12.022_b0225","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jocn.2012.12.022_b0230","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jocn.2011.01.031","article-title":"Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse","volume":"18","author":"Wang","year":"2011","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.jocn.2012.12.022_b0235","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ana.23651","article-title":"Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter","volume":"72","author":"Varrin-Doyer","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2012.12.022_b0240","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jneuroim.2011.03.009","article-title":"Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis","volume":"234","author":"Li","year":"2011","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jocn.2012.12.022_b0245","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1172\/JCI25141","article-title":"IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis","volume":"115","author":"Kaplin","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jocn.2012.12.022_b0250","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/ana.22551","article-title":"Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms","volume":"70","author":"Zhang","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2012.12.022_b0255","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1742-2094-7-52","article-title":"Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance","volume":"7","author":"Jarius","year":"2010","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.jocn.2012.12.022_b0260","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/archneurol.2011.148","article-title":"Markedly elevated soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 levels, and blood-brain barrier breakdown in neuromyelitis optica","volume":"68","author":"Uzawa","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jocn.2012.12.022_b0265","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","article-title":"Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo","volume":"66","author":"Bradl","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2012.12.022_b0270","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1212\/WNL.0b013e3181a82621","article-title":"A case of NMO seropositive for aquaporin-4 antibody more than 10years before onset","volume":"72","author":"Nishiyama","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2012.12.022_b0275","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00415-011-6288-2","article-title":"Seroconversion of anti-aquaporin-4 antibody in NMO spectrum disorder: a case report","volume":"259","author":"Mori","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2012.12.022_b0280","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jnnp-2011-300434","article-title":"Sera from neuromyelitis optica patients disrupt the blood\u2013brain barrier","volume":"83","author":"Shimizu","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2012.12.022_b0285","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archneurol.2007.17","article-title":"Neuromyelitis optica and non organ-specific autoimmunity","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jocn.2012.12.022_b0290","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jns.2009.08.040","article-title":"Association of anti-aquaporin-4 antibody-positive neuromyelitis optica with myasthenia gravis","volume":"287","author":"Uzawa","year":"2009","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2012.12.022_b0295","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1212\/WNL.0b013e31825644ff","article-title":"Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients","volume":"78","author":"Leite","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2012.12.022_b0300","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/ana.21753","article-title":"\u201cCloud-like enhancement\u201d is a magnetic resonance imaging abnormality specific to neuromyelitis optica","volume":"66","author":"Ito","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2012.12.022_b0305","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/archneur.63.3.390","article-title":"Brain abnormalities in neuromyelitis optica","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jocn.2012.12.022_b0310","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/archneur.63.7.964","article-title":"Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jocn.2012.12.022_b0315","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1212\/01.wnl.0000183151.19351.82","article-title":"Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica","volume":"65","author":"Misu","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2012.12.022_b0320","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00415-009-0139-4","article-title":"Narcolepsy as an initial manifestation of neuromyelitis optica with anti-aquaporin-4 antibody","volume":"256","author":"Baba","year":"2009","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2012.12.022_b0395","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/1352458512454772","article-title":"Diffuse and heterogeneous T2-hyperintense lesions in the splenium are characteristic of neuromyelitis optica","volume":"19","author":"Makino","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2012.12.022_b0330","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/1352458509103301","article-title":"Occurrence of acute large and edematous callosal lesions in neuromyelitis optica","volume":"15","author":"Nakamura","year":"2009","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2012.12.022_b0335","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00415-008-0545-z","article-title":"Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study","volume":"255","author":"Nakamura","year":"2008","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2012.12.022_b0340","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/WNO.0b013e318254c62d","article-title":"Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis","volume":"32","author":"Khanna","year":"2012","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.jocn.2012.12.022_b0345","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1212\/01.wnl.0000345042.53843.d5","article-title":"Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis","volume":"72","author":"Naismith","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2012.12.022_b0350","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/1352458506071174","article-title":"Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica","volume":"13","author":"Watanabe","year":"2007","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2012.12.022_b0355","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jocn.2012.12.022_b0360","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.jocn.2012.12.022_b0365","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2012.12.022_b0370","article-title":"Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab","author":"Araki","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jocn.2012.12.022_b0375","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ana.22657","article-title":"Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica","volume":"71","author":"Tradtrantip","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2012.12.022_b0380","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ana.22686","article-title":"Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain","volume":"71","author":"Saadoun","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2012.12.022_b0385","unstructured":"MS-UK. <http:\/\/www.msrc.co.uk\/index.cfm\/fuseaction\/show\/pageid\/2325>; 2013 [accessed 15.02.13]."}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586813001409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586813001409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:15:57Z","timestamp":1760822157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586813001409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0967586813001409"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2012.12.022","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuromyelitis optica: Concept, immunology and treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2012.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}